Skip NavigationSkip to Content
Return Return to Search Results

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

  1. Author:
    Fong, Youyi
    Dang, Lauren
    Zhang, Bo
    Fintzi, Jonathan
    Chen, Shiyu
    Wang, Jing
    Rouphael, Nadine G
    Branche, Angela R
    Diemert, David J
    Falsey, Ann R
    Losada, Cecilia
    Baden, Lindsey R
    Frey, Sharon E
    Whitaker, Jennifer A
    Little, Susan J
    Kamidani, Satoshi
    Walter, Emmanuel B
    Novak, Richard M
    Rupp, Richard
    Jackson, Lisa A
    Yu, Chenchen
    Magaret, Craig A
    Molitor, Cindy
    Borate, Bhavesh
    Babu, Tara M
    Kottkamp, Angelica C
    Luetkemeyer, Anne F
    Immergluck, Lilly C
    Presti, Rachel M
    Bäcker, Martín
    Winokur, Patricia L
    Mahgoub, Siham M
    Goepfert, Paul A
    Fusco, Dahlene N
    Atmar, Robert L
    Posavad, Christine M
    Mu, Jinjian
    Makowski, Mat
    Makhene, Mamodikoe K
    Nayak, Seema U
    Roberts, Paul C
    Follmann, Dean
    Gilbert, Peter B [ORCID]

  2. Author Address

    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington, USA., Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hope Clinic, Emory University, Decatur, Georgia, USA., Vaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA., George Washington Vaccine Research Unit, George Washington University, Washington, District of Columbia, USA., Department of Medicine, Brigham and Women 39;s Hospital, Harvard Medical School, Boston, Massachusetts, USA., Center for Vaccine Development, Saint Louis University, Missouri, USA., Department of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA., Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA., Center for Childhood Infections and Vaccines, Children 39;s Healthcare of Atlanta, Georgia, USA., Department of Pediatrics, Emory University, Atlanta, Georgia, USA., Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA., Project WISH, University of Illinois at Chicago, Chicago, Illinois, USA., Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA., Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA., Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA., Vaccine and Treatment Evaluation Unit, Manhattan Research Clinic, New York University Grossman School of Medicine, New York, New York, USA., Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California, USA., Clinical Research Center, Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA., Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA., Vaccine and Treatment Evaluation Unit, Long Island Research Clinic, New York University, Long Island School of Medicine, Mineola, New York, USA., Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA., Howard University College of Medicine, Howard University Hospital, Washington, District of Columbia, USA., Department of Medicine, University of Alabama at Birmingham, Alabama, USA., Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA., Infectious Diseases Clinical Research Consortium (IDCRC) Laboratory Operations Unit, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA., The Emmes Company, LLC, Rockville, Maryland, USA., Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.,
    1. Year: 2024
    2. Date: Sep 26
    3. Epub Date: 2024 09 26
  2. Journal: Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America
  4. Type of Article: Article
  5. Article Number: ciae465
  1. Abstract:

    For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/cid/ciae465
  3. PMID: 39325506
  4. PII : 7777106

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel